CBOC.F · Celsion Corporation

-

Please sign in to comment on CBOC.F

1 Comment

Admin

3 years, 7 months ago

Celsion Corporation is currently in a long term downtrend where the price is trading 0.4% below its 200 day moving average.

From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 88.4.

Celsion Corporation's total revenue sank by 0.0% to $125K since the same quarter in the previous year.

Its net income has increased by 2.9% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 33.6% to $-4M since the same quarter in the previous year.

Based on the above factors, Celsion Corporation gets an overall score of 3/5.

ISIN	None
Industry	Biotechnology
Sector	Healthcare
CurrencyCode	EUR
Exchange	F

Dividend Yield	0.0%
PE Ratio	None
Market Cap	2M
Target Price	3
Beta	1.9

ABOUT

Celsion Corporation

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

CBOC.F · Celsion Corporation

-

Celsion Corporation

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Celsion Corporation using a moving average strategy